Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
25.74 USD | -0.35% |
|
-2.94% | -2.98% |
Feb. 07 | AbbVie Gets FDA Approval of Intravenous Antibiotic Emblaveo | DJ |
Feb. 07 | US FDA approves AbbVie-Pfizer's treatment for intra-abdominal infections | RE |
Fiscal Period: December | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|---|---|---|---|
Revenues | 51.75B | 41.91B | 81.29B | 100B | 58.5B | |||||
Total Revenues | 51.75B | 41.91B | 81.29B | 100B | 58.5B | |||||
Cost of Goods Sold, Total | 10.01B | 8.57B | 30.66B | 34.1B | 23.99B | |||||
Gross Profit | 41.74B | 33.33B | 50.63B | 66.23B | 34.51B | |||||
Selling General & Admin Expenses, Total | 14.1B | 10.89B | 9.56B | 12.2B | 13.84B | |||||
R&D Expenses | 7.98B | 8.88B | 10.52B | 11.43B | 10.68B | |||||
Amortization of Goodwill and Intangible Assets - (IS) | 4.61B | 3.44B | 3.7B | 3.61B | 4.73B | |||||
Other Operating Expenses, Total | 26.7B | 23.2B | 23.78B | 27.24B | 29.25B | |||||
Operating Income | 15.04B | 10.13B | 26.84B | 39B | 5.26B | |||||
Interest Expense, Total | -1.57B | -1.45B | -1.29B | -1.24B | -2.21B | |||||
Interest And Investment Income | 446M | 351M | 202M | 565M | 2.1B | |||||
Net Interest Expenses | -1.13B | -1.1B | -1.09B | -673M | -109M | |||||
Income (Loss) On Equity Invest. | 17M | 298M | 471M | 436M | 505M | |||||
Currency Exchange Gains (Loss) | -172M | - | -192M | -1.15B | 164M | |||||
Other Non Operating Income (Expenses) | 1.31B | 2.29B | 1.88B | 2.62B | 1.28B | |||||
EBT, Excl. Unusual Items | 15.07B | 11.62B | 27.92B | 40.22B | 7.09B | |||||
Restructuring Charges | -1.28B | -859M | -1.36B | -2.02B | -3.33B | |||||
Merger & Related Restructuring Charges | -2M | -528M | - | -200M | -668M | |||||
Gain (Loss) On Sale Of Investments | 8.54B | 546M | 1.34B | -1.27B | 1.59B | |||||
Gain (Loss) On Sale Of Assets | 31M | -237M | 99M | - | 222M | |||||
Asset Writedown | -2.84B | -1.69B | -86M | -421M | -3.02B | |||||
In Process R&D Expenses | - | - | - | -953M | -194M | |||||
Insurance Settlements | 50M | - | - | - | - | |||||
Legal Settlements | -472M | -28M | -182M | -230M | -474M | |||||
Other Unusual Items | -1.42B | -1.32B | -3.42B | -394M | -157M | |||||
EBT, Incl. Unusual Items | 17.68B | 7.5B | 24.31B | 34.73B | 1.06B | |||||
Income Tax Expense | 1.38B | 477M | 1.85B | 3.33B | -1.12B | |||||
Earnings From Continuing Operations | 16.3B | 7.02B | 22.46B | 31.4B | 2.17B | |||||
Earnings Of Discontinued Operations | 4M | 2.63B | -434M | 6M | -15M | |||||
Net Income to Company | 16.3B | 9.65B | 22.02B | 31.41B | 2.16B | |||||
Minority Interest | -29M | -36M | -45M | -35M | -39M | |||||
Net Income - (IS) | 16.27B | 9.62B | 21.98B | 31.37B | 2.12B | |||||
Preferred Dividend and Other Adjustments | 1M | - | - | - | - | |||||
Net Income to Common Incl Extra Items | 16.27B | 9.62B | 21.98B | 31.37B | 2.12B | |||||
Net Income to Common Excl. Extra Items | 16.27B | 6.98B | 22.41B | 31.37B | 2.13B | |||||
Per Share Items | ||||||||||
Net EPS - Basic | 2.92 | 1.73 | 3.92 | 5.59 | 0.38 | |||||
Basic EPS - Continuing Operations | 2.92 | 1.26 | 4 | 5.59 | 0.38 | |||||
Basic Weighted Average Shares Outstanding | 5.57B | 5.56B | 5.6B | 5.61B | 5.64B | |||||
Net EPS - Diluted | 2.87 | 1.71 | 3.85 | 5.47 | 0.37 | |||||
Diluted EPS - Continuing Operations | 2.87 | 1.24 | 3.93 | 5.47 | 0.37 | |||||
Diluted Weighted Average Shares Outstanding | 5.68B | 5.63B | 5.71B | 5.73B | 5.71B | |||||
Normalized Basic EPS | 1.69 | 1.3 | 3.11 | 4.48 | 0.78 | |||||
Normalized Diluted EPS | 1.65 | 1.28 | 3.05 | 4.38 | 0.77 | |||||
Dividend Per Share | 1.44 | 1.52 | 1.56 | 1.6 | 1.64 | |||||
Payout Ratio | 49.43 | 87.77 | 39.72 | 28.63 | 436.38 | |||||
American Depositary Receipts Ratio (ADR) | 0.25 | 0.25 | 0.25 | 0.25 | 0.25 | |||||
Supplemental Items | ||||||||||
EBITDA | 21.01B | 14.89B | 31.95B | 44.02B | 11.52B | |||||
EBITA | 19.65B | 13.56B | 30.54B | 42.6B | 9.99B | |||||
EBIT | 15.04B | 10.13B | 26.84B | 39B | 5.26B | |||||
EBITDAR | 21.71B | 15.66B | 32.84B | 45.24B | 12.8B | |||||
Total Revenues (As Reported) | - | - | - | - | 58.5B | |||||
Effective Tax Rate - (Ratio) | 7.83 | 6.36 | 7.62 | 9.58 | -105.39 | |||||
Current Domestic Taxes | -1.94B | 429M | 3.38B | 2.72B | 1.19B | |||||
Current Foreign Taxes | 2.9B | 1.52B | 2.77B | 4.37B | 1.14B | |||||
Total Current Taxes | 958M | 1.95B | 6.14B | 7.09B | 2.33B | |||||
Deferred Domestic Taxes | 1.35B | -1.18B | -4.34B | -3.58B | -2.79B | |||||
Deferred Foreign Taxes | -919M | -292M | 48M | -183M | -652M | |||||
Total Deferred Taxes | 427M | -1.47B | -4.29B | -3.76B | -3.44B | |||||
Normalized Net Income | 9.39B | 7.23B | 17.4B | 25.11B | 4.39B | |||||
Interest Capitalized | 88M | 96M | 108M | 124M | 160M | |||||
Non-Cash Pension Expense | 206M | -76M | -2.14B | -247M | -508M | |||||
Supplemental Operating Expense Items | ||||||||||
Advertising Expense | 2.6B | 1.8B | 2B | 2.8B | 3.7B | |||||
Selling and Marketing Expenses | 2.6B | 1.8B | 2B | 2.8B | 3.7B | |||||
Research And Development Expense From Footnotes | 8.65B | 9.4B | 13.83B | 11.43B | 10.68B | |||||
Net Rental Expense, Total | 700M | 773M | 888M | 1.22B | 1.28B | |||||
Imputed Operating Lease Interest Expense | 195M | 202M | 240M | 329M | 424M | |||||
Imputed Operating Lease Depreciation | 505M | 571M | 648M | 889M | 859M | |||||
Stock-Based Comp., Other (Total) | 738M | 776M | 1.2B | 891M | 545M | |||||
Total Stock-Based Compensation | 738M | 776M | 1.2B | 891M | 545M |